ClinicalTrials.gg
RecruitingNCT07406724Updated Oct 27, 2026

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma(FASTIL-Mela02)

A Phase 2 interventional study of Tumor Tissue Sampling and Lymphodepletion Conditioning in Melanoma (Excluding Uveal Melanoma), sponsored by Hangzhou Huasai Biomedicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Hangzhou Huasai Biomedicine Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 27, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
64th of 189
90 · median 50
Started
2026
with 19 others
Phase 2
75 of 203
30 open now
Primary completion
2027-12
later than 59 of 94 live
Registered
183rd of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 64th largest by planned enrollment of the 189 interventional ones that give a count, is one of 20 that started in 2026, is one of 75 in phase 2, reaches primary completion later than 59 of the 94 other live ones, and was the 183rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced melanoma. A total of 90 participants are planned to be enrolled, and eligible participants will be randomly assigned to the experimental group or control group at a 1:1 ratio. The experimental group will receive a single administration of autologous tumor-infiltrating lymphocyte therapy, while the control group will receive chemotherapy regimens selected by the research physicians. Efficacy and safety evaluations will be conducted for all enrolled participants throughout the study.

03

Conditions studied

  • Melanoma (Excluding Uveal Melanoma)

Browse trials for

Keywords

  • Advanced Melanoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 18 to 75 years, inclusive.
  2. Patients with or histologically confirmed unresectable advanced, recurrent, or melanoma (excluding uveal melanoma), who have experienced disease progression after failure of systemic therapy recommended in the 2025 CSCO Guidelines.
  3. Disease Progression Following Anti- Therapy.
  4. At least one tumor lesion not treated with radiotherapy or other local therapies within 28 days prior to resection, suitable for autologous tumor-infiltrating lymphocyte (TIL) preparation, with a minimum tissue weight of ≥0.050 g.
  5. At least one measurable tumor lesion per 1.1 after tumor tissue sampling.
  6. performance status ≤ 1.
  7. Expected survival ≥ 3 months.
  8. Adequate organ and bone marrow function as confirmed by screening assessments.
  9. Documented by echocardiography showing (LVEF) ≥50%;Absence of arrhythmia requiring therapeutic intervention; (ECG) criteria; corrected by Frederica's formula (QTcF) ≤470 ms;Baseline peripheral oxygen saturation (SpO₂) >91% in room air.
  10. Adverse reactions from prior therapy have resolved to v5.0 grade ≤1 before randomization, except for hypothyroidism and alopecia judged by the investigator as non-safety concerns.
  11. Effective non-pharmacological measures must be used from the signing of the form until 1 year after TIL cell infusion.
  12. The subject fully understands the trial, voluntarily provides written informed consent, and is able to comply with scheduled visits and protocol-specified procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of severe reactions (e.g., anaphylaxis, Stevens-Johnson syndrome, or toxic epidermal necrolysis) to any component of the following agents.
  2. Presence of any uncontrolled clinical conditions, including but not limited to:

    • Poorly controlled hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg at rest despite antihypertensive therapy);
    • Congestive heart failure ( Class III/IV).
  3. History of deep vein thrombosis (DVT) or pulmonary embolism (PE); myocardial infarction; severe or unstable arrhythmia or angina; percutaneous coronary intervention, acute coronary syndrome, or coronary artery bypass grafting; cerebrovascular accident, , or cerebral embolism within the past 6 months.
  4. Active diseases requiring systemic therapy during the study period(Subjects with the following conditions may be enrolled:Eczema, vitiligo, psoriasis, alopecia, or Graves' disease not requiring systemic therapy within the last 2 years and not expected to recur, or other autoimmune diseases under stable control;Hypothyroidism requiring only thyroid hormone replacement;Type 1 diabetes requiring only insulin replacement therapy.)
  5. Organ transplant or history of hematopoietic stem cell transplantation.
  6. Use of systemic agents (e.g., ) within 4 weeks prior to randomization, or presence of comorbid conditions requiring such medications during the trial period.Exception: Intranasal or topical corticosteroids are permitted.
  7. Receipt of systemic anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization, or planned participation in another interventional clinical trial during the study period.
  8. Acute or chronic infections, including:

    • -positive status, Treponema pallidum antibody positivity, or clinically active or C(Note: For hepatitis B, HBsAg- or HBeAg-positive individuals with HBV DNA below the lower limit of normal at the study site may be enrolled; for , HCVAb-positive individuals with HCV RNA below the lower limit of normal at the study site may be enrolled);
    • Active infections requiring systemic therapy or active tuberculosis infection.
  9. Subjects who received any within 3 months prior to screening or planning to receive live vaccines during the trial period.
  10. Subjects who have undergone major organ surgery or experienced trauma within 4 weeks prior to screening, or require elective surgery during the trial period.
  11. Patients presenting with pre-screening surgical complications or delayed wound healing, and deemed by the investigator to confer increased risks during lymphodepleting pretreatment, adoptive TIL therapy, and high-dose IL-2 therapy.
  12. Patients with a history of other primary diagnosed within 5 years prior to screening are excluded, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or carcinoma in situ.
  13. Patients with severe respiratory diseases (including but not limited to a documented history of or concurrent severe interstitial lung disease (ILD), severe (COPD), profound pulmonary insufficiency, or symptomatic bronchospasm).
  14. Patients requiring surgical intervention for gastrointestinal hemorrhage, localized intestinal ischemia, or intestinal perforation.
  15. Patients with symptomatic central nervous system (CNS)
  16. Patients with clinical symptoms of central nervous system (CNS) metastases who have received prior therapy for and maintained radiographic stability (confirmed by MRI) for at least 12 weeks may be enrolled.
  17. Pregnant or lactating women.
  18. Individuals with a known history of psychiatric disorders, alcoholism, drug abuse, or substance abuse, as well as any other conditions deemed unsuitable for participation by the investigator .
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HS-IT101 monotherapy

    Tumor Tissue Sampling、Bridging Therapy、Lymphodepletion Conditioning、Infusion of HS-IT101 Injection、IL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy

    Procedure: Tumor Tissue Sampling · Drug: Lymphodepletion Conditioning · Drug: Infusion of HS-IT101 Injection · Drug: IL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy

  • Active comparator
    Investigator's Choice of Chemotherapy Regimens

    Drug: Investigator's selection of appropriate chemotherapy regimen

Interventions

  • ProcedureTumor Tissue Sampling

    Surgical procurement of the subject's tumor tissue for autologous tumor-infiltrating lymphocyte (TIL) preparation

  • DrugLymphodepletion Conditioning

    Intravenous Infusion of Cyclophosphamide and Fludarabine

  • DrugInfusion of HS-IT101 Injection

    Single intravenous infusion of HS-IT101 Injection following lymphodepletion conditioning

  • DrugIL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy

    Subcutaneous injection of IL-2 following intravenous infusion of HS-IT101 Injection

  • DrugInvestigator's selection of appropriate chemotherapy regimen

    Single-agent or combination chemotherapy regimens include dacarbazine, temozolomide, paclitaxel, and carboplatin.

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-Free Survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: 1 year

Secondary outcomes

  1. OS

    Time from randomization to death from any cause, as well as 6-month and 12-month Overall Survival (OS) rates

    Time frame: 1 year

  2. ORR

    Proportion of subjects with best overall response (BOR) of either partial response (PR) or complete response (CR)

    Time frame: 1 year

  3. DCR

    Proportion of subjects with best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among total evaluable cases

    Time frame: 1 year

  4. DOR

    The time from first documentation of complete response (CR) or partial response (PR) to first documented progressive disease (PD) or all-cause death, whichever occurs first

    Time frame: 1 year

  5. TTR

    Time to First Response (TTR) from randomization in participants with a best overall response (BOR) of Complete Response (CR) or Partial Response (PR)

    Time frame: 1 year

  6. PFS

    Progression-Free Survival (PFS) assessed by Investigator

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 22 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 12, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Cancer Hospital · Beijing, China
Oct 27, 2026
Title
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma(FASTIL-Mela02)
Oct 27, 2026
Sponsor
Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Beijing Cancer Hospital · Beijing, China
    Sponsor Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
    Title HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma(FASTIL-Mela02)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07406724
Lead sponsor
Hangzhou Huasai Biomedicine Co., Ltd.
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 26, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion